**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 62890

**Manuscript Type:** CASE REPORT

**Escitalopram-induced hepatitis: A case report**

Wabont G. *et al*. Escitalopram induced hepatitis and cholestasis

Guillaume Wabont, Laurie Ferret, Nicolas Houdre, Antoine Lepied, Johana Bene, Etienne Cousein

**Guillaume Wabont, Laurie Ferret, Etienne Cousein,** Department of Pharmacy, Valenciennes Hospital, Valenciennes 59300, France

**Nicolas Houdre,** Department of Emergency Medicine, Valenciennes Hospital, Valenciennes 59300, France

**Antoine Lepied,** Department of Psychiatry, Valenciennes Hospital, Valenciennes 59300, France

**Johana Bene,** Department of Pharmacology, Lille University Hospital, Lille 59000, France

**Author contributions:** Wabont G wrote the manuscript; and all authors contributed equally to this work and have read and approved the final manuscript.

**Corresponding author: Guillaume Wabont, PharmD, Pharmacist, Statistician,** Department of Pharmacy, Valenciennes Hospital, Avenue Desandrouin, Valenciennes 59300, France. wabont.guillaume@gmail.com

**Received:** August 11, 2021

**Revised:** September 23, 2021

**Accepted:** February 9, 2022

**Published online:** March 16, 2022

**Abstract**

BACKGROUND

The antidepressant escitalopram is widely prescribed for the treatment of depression. It is generally well-tolerated, and cholestasis is not mentioned in its summary of product characteristics (SmPC). We present a case of cholestatic and cytolysis liver injury due to escitalopram and a VigiBase® study.

CASE SUMMARY

A 68-year-old man was admitted to our emergency unit due to clinical jaundice associated with hepatitis, pruritus and dark urine. We tested the patient for the most common etiologies of jaundice, including hemolysis, viral hepatitis, cirrhosis, carcinoma, cholangitis, cholelithiasis and intrahepatic or extrahepatic obstruction. The etiological study was negative, and an adverse drug reaction was the sole possible explanation. The patient was receiving treatment with escitalopram. Two days after its withdrawal, pruritus was resolved. Ten days after withdrawal, clinical jaundice disappeared. It took a month and three weeks after withdrawal for the patient to have normalized liver function tests. To our knowledge, this is the first reported case of cholestasis where treatment with escitalopram was the only possible cause, with a highly probable causality. In addition, we determined whether escitalopram is associated with hepatotoxicity and cholestasis by performing a disproportionality analysis. All cases of hepatobiliary disorders induced by escitalopram and reported in the World Health Organization pharmacovigilance database (VigiBase®) were analyzed to characterize this toxicity. We found that patients treated with escitalopram had an increased risk of hepatitis [odds ratio (OR) = 1.938(1.186-3.166)] and cholestasis [OR = 1.866(1.279-2.724)] [OR (95% confidence interval)]. The median duration between the introduction of escitalopram and the occurrence of acute hepatitis and/or cholestasis was ten days +/- seven days.

CONCLUSION

Although extremely rare, this case report, the review of the literature and the pharmacovigilance update confirm that escitalopram can cause drug-induced hepatotoxicity and cholestasis, generally within a week after initiation. Thus, escitalopram should be withdrawn immediately if an iatrogenic cause cannot be excluded. If its responsibility is ascertained, escitalopram should be consequently contraindicated. In addition, serotoninergic antidepressants in patients with non-severe depression are ineffective and harmful. Finally, the SmPC of escitalopram should be updated to alert for this risk and give clear clinical guidelines.

**Key Words:** Escitalopram; Hepatitis; Cholestasis; Pharmacovigilance; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Wabont G, Ferret L, Houdre N, Lepied A, Bene J, Cousein E. Escitalopram-induced hepatitis: A case report. *World J Clin Cases* 2022 ; 10(8): 2468-2473

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i8/2468.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i8.2468

**Core Tip:** The antidepressant escitalopram is widely prescribed for the treatment of depression. The article consists of a unique clinical case, a review of the literature and a pharmacovigilance analysis. This is the first clinical case of escitalopram as the only possible drug causing hepatitis and cholestasis. This is also the first pharmacovigilance analysis conducted to qualify and quantify the risk of hepatitis and cholestasis when using escitalopram.

**INTRODUCTION**

Depression is a common mental disorder worldwide and a leading cause of non-fatal health loss, affecting more than 264 million people[1].

Among the antidepressants, selective serotonin reuptake inhibitors are often prescribed as a first-line treatment. They increase the intrasynaptic levels of serotonin by inhibiting the neurotransmitter's reuptake into the presynaptic neuron. However, the benefits of antidepressants are known to be minimal or ever non-existent in patients with mild to moderate symptoms, uselessly exposing them to potential adverse drug reactions[2]. Drug-induced liver injury is a rare complication of antidepressants and is a concern mainly for tricyclic and tetracyclic antidepressants[3].

Here we present a case of cholestatic and cytolysis liver injury due to escitalopram, a selective serotonin reuptake inhibitor, and a VigiBase® study.

**CASE PRESENTATION**

***Chief complaints***

The 68-year-old Caucasian male patient, was prescribed escitalopram 5 mg/d by his general practitioner for a minor depressive episode; the posology rose to 10 mg/d one week later. The patient developed clinical icterus with pale stools and dark urine three days later, without any pain or hyperthermia.

***History of present illness***

The patient was admitted to the emergency unit three days later. He was then transferred to the gastroenterology and hepatology unit, where an etiologic investigation was performed[4].

The moderate daily intake of alcohol (less than 10 g/d) and the absence of damaged hepatocytes, cirrhosis or carcinoma excluded hepatocellular jaundice.

***History of past illness***

The patient had no history of past illness, chronic treatment or known allergies.

***Personal and family history***

No notable personal or family history.

***Physical examination***

A physical examination was unremarkable, except for palpable hepatomegaly, eliminating an obstructive cause. Etiologies such as cholangitis, pancreatic carcinoma or edema, cholelithiasis and trauma were not found.

***Laboratory examinations***

Normochromic and normocytic anemia, a subtle inflammatory syndrome, cholestasis with conjugated hyperbilirubinemia and cytolytic hepatitis were observed (Table 1). The presence of conjugated bilirubin and the absence of hemolysis excluded pre-hepatic jaundice. A viral cause was improbable due to the absence of hyperthermia, and human immunodeficiency virus (HIV), hepatitis viruses (HAV, HBV, HCV, HEV), cytomegalovirus (CMV) and herpes simplex viruses (HSV) serologies were negative. Autoantibodies and serum immunoglobulin levels were not screened.

***Imaging examinations***

Hepatic ultrasonography was unremarkable.

**FINAL DIAGNOSIS**

Considering the lack of probing results from the etiologic investigation and the spontaneous resolution of symptoms after treatment was withdrawn, the only possible remaining cause was drug-induced cholestatic and cytolytic hepatitis due to escitalopram.

**TREATMENT**

Treatment with escitalopram was immediately stopped.

**OUTCOME AND FOLLOW-UP**

The chronopathology was as follows: The symptoms started to appear ten days after initiation of treatment. Pruritus resolved two days after escitalopram withdrawal. Clinical jaundice disappeared ten days after withdrawal. Liver function tests normalized a month after withdrawal. It should be noted that bilirubin levels normalized more rapidly than transaminase levels, which is not common in clinical practice, especially in drug-induced liver injury (DILI)[5]. However, we are unable to explain this phenomenon.

**DISCUSSION**

***Case report description***

We used the Roussel Uclaf Causality Assessment Method (RUCAM) to quantify the strength of the association between cholestatic hepatitis and treatment with escitalopram[6,7]. The RUCAM comprises seven criteria: The time to onset of reaction after drug start, clinical course, risk factors, concomitant drugs with hepatotoxic properties, non-drug causes, and published information on hepatotoxicity and the response to any new administration to the suspected drug. The RUCAM score ranges from -8 to +14. A higher score means a higher probability of DILI as it is collapsed into the following five-category scale: Highly probable (> 8), probable (6-8), possible (3-5), unlikely (1-2), and excluded (≤ 0).

According to the RUCAM, the iatrogenic cause of both hepatitis (10/14) and cholestasis (9/14) in our case was highly probable (Supplementary material).

***Literature review***

Eligible studies were identified through electronic searches of Medline and Embase (1966 to May 2020), using different sets of keywords. The first set consisted of “escitalopram” and “citalopram”; the second set of “cholestasis” and “hepatitis”, the third one (optional) of “iatrogeny” and “drug-induced”.

In addition, we reviewed the reference lists in the articles. Voican *et al*[3] wrote a review for clinicians on antidepressant-induced liver injury. Helmut *et al*[11] described a case of cholestasis and acute hepatitis three weeks after introducing citalopram in a 56-year-old woman. Milkiewicz *et al*[12] described a case of cholestasis and acute hepatitis two months after introducing citalopram 10 mg/d (posology rose to 20 mg/d one month later). Finally, Ng *et al*[13] described a case of cholestasis two weeks after the introduction of escitalopram and olanzapine in a 56-year-old woman.

Few cases have proved that hepatic cholestasis can rarely be caused by citalopram[11,12]. Since citalopram is a racemic composed of 50% R-citalopram and 50% escitalopram, it was plausible that such a rare adverse event could be due to escitalopram. Only recently, Ng *et al*[13] described a case of cholestasis due to escitalopram in a 56-year-old woman: The first clinical signs of cholestasis appeared two weeks after escitalopram was initiated. The RUCAM score showed a probable iatrogenic cause. The patient was treated with other drugs, and olanzapine was introduced four days before escitalopram. Olanzapine is also labelled as a cause a cholestasis[14], and up to 28% of patients experience elevated hepatic enzymes. Therefore, in the case presented by Ng *et al*[13], it may well have participated in hepatic toxicity. In our case, escitalopram was the only drug taken by the patient, and thus its sole contribution to hepatic toxicity is certain, making this case unique.

Milkiewicz *et al*[12] have made assumptions on the pathophysiological mechanism involving the hepatocellular redistribution of multidrug-resistant protein 2, one of the key canalicular proteins responsible for transporting several organic anions, including bilirubin glucuronides, from the hepatocyte to bile. However, the exact mechanism of such hepatotoxicity remains unclear and needs to be investigated.

Pharmacovigilance analysis of hepatitis and cholestasis induced by escitalopram was investigated using Vigibase®, which is the most extensive pharmacovigilance database. It contains more than 24 million individual case safety reports (ICSRs) submitted by national pharmacovigilance centers from countries all over the world within the World Health Organization pharmacovigilance program.

We used Vigibase® to describe the characteristics of the hepatobiliary disorders associated with escitalopram[8]. We searched for all ICSRs presenting at least one adverse drug reaction from a defined list related to escitalopram with a minimal set of data (Table 2), submitted from the 14th November 1967 to 7th May 2020. A total of 481 ICSRs were analyzed, but only 127 ICSRs matched our specific criteria of cholestasis and/or hepatitis (Table 2), presumably caused by escitalopram. For each of those 127 ICSRs, we collected the following data: Age and sex of the patient, time between the introduction of escitalopram and the hepatobiliary disorder, withdrawal of escitalopram, necessity for hospitalization and the recovery from hepatobiliary disease after it was diagnosed.

We also performed a disproportionality analysis from the data extracted from Vigibase® between the adverse reactions “hepatitis acute (PT)” or “cholestasis (PT)” and escitalopram treatment using the case/non-case method. The strength of the association was quantified by crude reporting OR with their 95% confidence interval[9,10]. Statistical methods are detailed in Supplementary material.

Statistical significance was defined as a *P*-value threshold of 0.05. Statistical analyses were performed in SAS 9.4 (SAS Institute, Cary NC, United States).

With regard to the 127 ICSRs included for the characterization of hepatitis or cholestasis secondary to the intake of escitalopram, most of the patients were women (64.6%). The median (interquartile) age was 35(49-62.75) years old.

The mean duration between the introduction of escitalopram and the occurrence of hepatitis or cholestasis was ten days +/- seven days.

Cases of cytolytic hepatitis (28 ICSRs - 22.0%) seemed to be more frequent than cases of cholestasis (19 ICSRs - 15.0%). Only 2 ICSRs (1.6%) corresponded to mixed cholestatic and cytolytic hepatitis.

The toxicity of escitalopram did not seem to be dose-dependent: In almost half of cases the prescribed posology was 10 mg/d (49.0%), followed by 20 mg/d (17.6%), 5 mg/d (8.6%) and 15 mg/d (5.5%).

The vast majority of cases included in the international pharmacovigilance database lacked data such as the chronology of healing after the withdrawal of escitalopram. However, from our case, we can hypothesize that clinical recovery occurs within a few days and biological normalization within a few weeks.

Among the 9372588 ICSRs included in the disproportionality analysis, 13071 involved escitalopram. Most of the patients were women (69.3%). Patient age was mainly between 45 and 64 years old (57.0%) followed by 65 and 74 years (21.3%), 18 and 44 years (13.9%), and ≥ 75 years (7.8%). A signal was found between acute hepatitis or cholestasis and exposure to escitalopram (Table 3).

Cholestasis is not mentioned in the summary of product characteristics (SmPC) of escitalopram in the EU or the United States. It should be noted that the American SmPC mentions a risk of delayed hyperbilirubinemia when taking escitalopram, with no further notice (incidence not known). Hepatitis is mentioned in both the European and American SmPC of escitalopram, with an unknown incidence.

Approximately two-thirds (64.6%) of the cases of hepatitis or cholestasis related to escitalopram found in Vigibase® concerned female patients. At first sight, this might indicate gender-based differences in the hepatic toxicity of escitalopram. However, it is well established that depression has a higher prevalence in women than in men: A recent United States national data study found a similar ratio[15]. Furthermore, the exact ratio applies to the number of cases of adverse drug reactions notified with escitalopram (69.3% of cases were female patients): It is unlikely that the hepatotoxicity of escitalopram differs according to gender.

The pharmacovigilance analysis confirmed that escitalopram could rarely cause acute hepatitis and cholestasis. However, the ICSRs in Vigibase® lack data, especially the course of clinical recovery and biological normalization after escitalopram withdrawal. Therefore, when confronted with hepatitis or cholestasis due to escitalopram, health practitioners must spontaneously report it to their local or national pharmacovigilance center and provide as many details as possible.

An interesting aspect of our case is that the general practitioner prescribed escitalopram for a minor depressive episode. A psychiatrist reexamined the patient during his hospitalization and diagnosed mild depression, with no need for an antidepressant drug. Thus, our case highlights something well established: Antidepressants are minimally helpful, if not useless and dangerous, in patients with mild to moderate depressive symptoms[2]. General practitioners and physicians should be aware of the ineffectiveness and harm of serotoninergic antidepressants in patients with non-severe depression.

**CONCLUSION**

Our case illustrates how inappropriate prescriptions can have severe consequences on both patients (*e.g.,* hospitalizations) and the health care system (evitable social security costs).

Although extremely rare, escitalopram can cause drug-induced hepatitis and cholestasis, generally within a week after initiation. Therefore, physicians must be aware of this rare but severe adverse effect. The SmPC of escitalopram should be updated to alert for this risk and give clear clinical guidelines. In the case of hepatitis or cholestasis, if an iatrogenic cause cannot be excluded, escitalopram must be immediately withdrawn and then contraindicated if its responsibility is ascertained.

**REFERENCES**

1 **GBD 2017 Disease and Injury Incidence and Prevalence Collaborators**. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1789-1858 [PMID: 30496104 DOI: 10.1016/S0140-6736(18)32279-7]

2 **Fournier JC**, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. *JAMA* 2010; **303**: 47-53 [PMID: 20051569 DOI: 10.1001/jama.2009.1943]

3 **Voican CS**, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. *Am J Psychiatry* 2014; **171**: 404-415 [PMID: 24362450 DOI: 10.1176/appi.ajp.2013.13050709]

4 **Fargo MV**, Grogan SP, Saguil A. Evaluation of Jaundice in Adults. *Am Fam Physician* 2017; **95**: 164-168 [PMID: 28145671]

5 **Avigan MI,** Muñoz MA. Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI). In: Chen M, Will Y, eds. Drug-Induced Liver Toxicity, Methods in Pharmacology and Toxicology. New York: Humana Press, 2018: 367-93

6 **Rochon J**, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. *Hepatology* 2008; **48**: 1175-1183 [PMID: 18798340 DOI: 10.1002/hep.22442]

7 **Katarey D**, Verma S. Drug-induced liver injury. *Clin Med (Lond)* 2016; **16**: s104-s109 [PMID: 27956449 DOI: 10.7861/clinmedicine.16-6-s104]

8 **Bate A**, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. *Fundam Clin Pharmacol* 2008; **22**: 127-140 [PMID: 18248442 DOI: 10.1111/j.1472-8206.2007.00552.x]

9 **Egberts AC**, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. *Drug Saf* 2002; **25**: 453-458 [PMID: 12071783 DOI: 10.2165/00002018-200225060-00010]

10 **European Medicines Agency (EMA)**. Guideline on good pharmacovigilance practices (GVP). Module IX Addendum I-Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. 2017

11 **Neumann H**, Csepregi A, Evert M, Malfertheiner P. Drug-induced liver disease related to citalopram. *J Clin Psychopharmacol* 2008; **28**: 254-255 [PMID: 18344747 DOI: 10.1097/JCP.0b013e318167b8e1]

12 **Milkiewicz P**, Chilton AP, Hubscher SG, Elias E. Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2). *Gut* 2003; **52**: 300-303 [PMID: 12524417 DOI: 10.1136/gut.52.2.300]

13 **Ng QX**, Yong CSK, Loke W, Yeo WS, Soh AYS. Escitalopram-induced liver injury: A case report and review of literature. *World J Hepatol* 2019; **11**: 719-724 [PMID: 31749902 DOI: 10.4254/wjh.v11.i10.719]

14 **Domínguez-Jiménez JL**, Puente-Gutiérrez JJ, Pelado-García EM, Cuesta-Cubillas D, García-Moreno AM. Liver toxicity due to olanzapine. *Rev Esp Enferm Dig* 2012; **104**: 617-618 [PMID: 23368661 DOI: 10.4321/s1130-01082012001100017]

15 **Hasin DS**, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. *JAMA Psychiatry* 2018; **75**: 336-346 [PMID: 29450462 DOI: 10.1001/jamapsychiatry.2017.4602]

**Footnotes**

**Informed consent statement:** The study participant provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**CARE Checklist (2016) statement:** The authors followed the CARE checklist guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** August 11, 2021

**First decision:** September 2, 2021

**Article in press:** February 9, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** France

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ferraioli G, Rao CY, Zheng SJ **S-Editor:** Wang JJ **L-Editor:** Webster JR **P-Editor:** Wang JJ

**Table 1 C-reactive protein and liver test levels (D0: Day when escitalopram was withdrawn)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Date** | **C-reactive protein (mg/L)** | **Total bilirubin (µmol/L)** | **Conjugated bilirubin (µmol/L)** | **Unconjugated bilirubin (µmol/L)** | **Alanine transa-minase (IU/L)** |
| D - 22 | < 5.00 | 4 |  |  |  |
| D0 | 8.20 | 101 | 65 | 36 | 80 |
| D + 1 | 7.80 | 109 | 66 | 43 | 77 |
| D + 3 | 15.00 | 117 | 69 | 48 | 72 |
| D + 4 | 13.90 | 115 | 71 | 44 | 69 |
| D + 16 |  | 84 | 46 | 38 | 58 |
| D + 20 |  | 50 | 24 | 26 |  |
| D + 29 | 6.90 | 25 | 11 | 14 | 43 |

**Table 2 Search criteria in Vigibase® (characterization of hepatitis or cholestasis)**

|  |  |
| --- | --- |
| **Adverse drug reactions list for extraction** | **The minimal set of data needed for extraction** |
| Cholestasis and jaundice (HLT); Hepatic and hepatobiliary disorders NEC (HLT); Hepatic enzymes and function abnormalities (HLT); Hepatobiliary signs and symptoms (HLT); Cholestatic liver injury (PT); Drug-induced liver injury (PT); Hepatitis (PT); Hepatitis acute (PT); Hepatitis toxic (PT); Hepatocellular injury (PT); Hepatotoxicity (PT) | Patient age above 18 years old; Patient gender specified in the ICSR |
| HLT and PT from the MedDRA® hierarchy |

HLT: High-level term; PT: Preferred term; ICSR: Individual case safety report; NEC: Necrotizing enterocolitis.

**Table 3 Reporting odds ratio of acute hepatitis and cholestasis in Vigibase® in patients receiving escitalopram**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **OR** | **95% CI** | ***P* value** |
| Acute hepatitis | 1.938 | 1.186-3.166 | 0.0083 |
| Cholestasis | 1.866 | 1.279-2.724 | 0.0012 |

OR: Odds ratio; CI: Confidence interval.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**